drugset / Trial / NCT06270836
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2026-02-13
- Completion
- 2026-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tarcocimab | Monoclonal antibody | 5 mg | Intravitreal |